Core Insights - The stock price of Tailin Biological closed at 27.2 yuan on November 27, with a 4.90% increase, resulting in a rolling PE ratio of 200.29 times and a total market capitalization of 3.297 billion yuan [1] - The average PE ratio in the medical device industry is 51.68 times, with a median of 40.10 times, placing Tailin Biological at the 114th position in the industry ranking [1] - As of September 30, 2025, the number of shareholders for Tailin Biological decreased by 1,487 to 9,437, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. specializes in microbial testing and pollution control, innovative drug research and production, process analysis, and protective measures, providing high-quality products and solutions for various industries including biomedicine, healthcare, food and beverage, and environmental protection [2] - The company has a portfolio of 419 technology patents, including 55 invention patents, and has participated in the formulation of 35 national and industry standards, with 17 of those as the first author [2] - Tailin Biological has undertaken three key projects under the "13th Five-Year National Science and Technology Innovation Plan" and received an award for technological innovation from the China Pharmaceutical Equipment Industry Association [2] Financial Performance - In the latest quarterly report for Q3 2025, Tailin Biological reported revenue of 213 million yuan, a year-on-year decrease of 12.08%, while net profit increased by 30.13% to 14.7233 million yuan, with a gross profit margin of 52.59% [2]

Core Viewpoint - Tailin Bio (300813.SZ) announced that its wholly-owned subsidiary, Tailin Analytical Instruments, has recently obtained a software copyright registration certificate for its software "Total Organic Carbon Detection Analysis and Data Processing Software V1.0" [1] Summary by Relevant Sections - **Software Copyright Registration** - The software copyright registration certificate number is 16842943, and the registration number is 2025SR2186745 [1] - **Impact on Operations** - The acquisition of the software copyright will not have a significant impact on the company's and its subsidiary's recent production and operations [1] - **Strategic Advantages** - This achievement is expected to enhance the company's and its subsidiary's intellectual property advantages, improve the intellectual property protection system, foster a continuous innovation mechanism, and elevate core competitiveness [1]

浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰林 分析仪器有限公司（以下简称"泰林分析仪器"）于近期共取得了 1 项计算机软 件著作权登记证书，具体情况如下： | 序号 | 软件名称 | 著作权人 | 证书号 | 首次发表日 期 | 登记日期 | 权利 取得 | 权利 范围 | 登记号 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 方式 | | | | | 总有机碳 | | | | | | | | | | 检测分析 | 泰林分析 | 软著登字第 | | | 原始 | 全部 | 2025SR21 | | 1 | 与数据处 | | 16842943 | 2025/7/22 | 2025/11/12 | | | | | | 理软件 | 仪器 | 号 | | | 取得 | 权利 | 86745 | | | V1.0 | | | | | | | | 上述计算机软件著作权登记证书的取得不会对公司及全资子公司泰林分析 仪器近期生产经营产生重大影响，但在一定程度上有利于发挥公司及全资子公司 泰林分析仪器的自主知 ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-083 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰林 生命科学有限公司（以下简称"泰林生命科学"）、浙江泰林医学工程有限公司（以 下简称"泰林医学工程"）于近期共取得了 3 项专利证书，具体情况如下： | 序号 | 专利名称 | 专利类型 | 申请号 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | | 1 | 一种过氧化氢汽化消毒机 | 实用新型 | 2024225569186 | 2025/11/7 | 泰林医学工程 | | 2 | 一种西林瓶翻转装置 | 实用新型 | 2024227562302 | 2025/11/7 | 泰林医学工程 | | 3 | 一种多用途的虹吸旋盖 | 实用新型 | 2024232559916 | 2025/11/7 | 泰林生命科学； 江苏宏众百德 生物科技有限 公司 | 上述专利的取得不会对公司及全资子公司泰林生命科学、泰林医学工程近期 生产经营产生重大影响，但有利于公司及全资子公司泰林生命科学、泰林医学工 程进一步完善知识产权保 ...

Core Viewpoint - Tailin Bio (300813) announced the acquisition of three invention patent certificates by its wholly-owned subsidiaries, Zhejiang Tailin Life Science Co., Ltd. and Zhejiang Tailin Medical Engineering Co., Ltd. [1] Company Summary - Tailin Bio's subsidiaries have recently obtained three invention patent certificates, indicating a focus on innovation and potential growth in their product offerings [1]

Group 1 - The core point of the news is that Tailin Bio has recently obtained three invention patents through its wholly-owned subsidiaries, indicating a focus on innovation and development in the biotechnology sector [1] - The patents include a "microbial elution solution and its preparation method and application" and a "sterile connector and sterile connection method," showcasing the company's advancements in medical technology [1] - For the fiscal year 2024, Tailin Bio's revenue composition is projected to be 90.04% from the pharmaceutical industry and 9.96% from other businesses, highlighting the company's strong reliance on its core pharmaceutical operations [1] Group 2 - As of the latest report, Tailin Bio has a market capitalization of 3.6 billion yuan, reflecting its position in the market [2]

Core Viewpoint - Tailin Bio has announced the receipt of three invention patent certificates from the National Intellectual Property Administration, indicating advancements in its product offerings and potential for innovation in the biotechnology sector [1] Group 1: Patent Details - The patents include "a microbial elution solution and its preparation method and application" [1] - Another patent is for "a sterile connector and sterile connection method" [1] - The third patent pertains to "a method, system, and storage medium for improving the accuracy of pump quantitative injection" [1]

浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰林 生命科学有限公司（以下简称"泰林生命科学"）、浙江泰林医学工程有限公司（以 下简称"泰林医学工程"）于近期共取得了 3 项发明专利证书，具体情况如下： | 序号 | 专利名称 | 专利类型 | 申请号 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | | 1 | 一种微生物洗脱液及其配制方法 和应用 | 发明 | 2025110170952 | 2025/10/31 | 泰林生命科学 | | 2 | 一种无菌连接器及无菌连接方法 | 发明 | 2023110142050 | 2025/10/31 | 泰林医学工程 | | 3 | 一种泵定量加注精度的提升方法、 系统及存储介质 | 发明 | 2024110229307 | 2025/10/31 | 泰林医学工程 | 证券代码：300813 证券简称：泰林生物 公告编号：2025-082 浙江泰林生物技术股份有限公司 关于取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 ...

Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. was listed on the Shenzhen Stock Exchange in January 2020, focusing on life science solutions, including biotechnology, precision medicine, pharmaceutical engineering, food safety, and new materials [3] - The company serves thousands of clients across various sectors, including pharmaceutical companies, food and drug inspection agencies, healthcare institutions, and research organizations [3] Market and Product Insights - The company is actively expanding its product applications in the semiconductor industry, with a focus on developing new technologies and products [4] - In 2025, the water ecology market is shifting towards comprehensive data, precise results, and practical new technologies, with an emphasis on risk management and monitoring [4] - Tailin's water ecology products include enzyme substrate detection systems and fully automated detection systems, addressing systemic needs in water monitoring and management [4] Financial Performance - The company's gross margin has improved significantly in the first half of 2025, primarily due to higher margins from its sterile production and contamination control equipment [5][6] - International business has seen notable growth, with higher unit prices and margins compared to domestic sales [6] Research and Development - R&D expenses account for 25% of the company's costs, focusing on life sciences, medical engineering, and analytical instruments [6] - Recent R&D priorities include water ecology detection, quality control in pharmaceutical health products, safety in major disease treatment drugs, and applications in the semiconductor sector [6]

Market Performance - The specialized equipment sector increased by 0.74% on November 3, with Tailin Bio leading the gains [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Top Gainers - Tailin Bio (300813) closed at 33.46, up 12.09% with a trading volume of 85,600 shares and a turnover of 285 million yuan [1] - Dahongli (300865) closed at 33.02, up 11.29% with a trading volume of 73,500 shares and a turnover of 235 million yuan [1] - Guojitongyong (600444) closed at 20.09, up 10.02% with a trading volume of 116,800 shares [1] - Dongfang Precision (002611) closed at 20.90, up 10.00% with a trading volume of 3.1185 million shares and a turnover of 6.358 billion yuan [1] Top Losers - Taidan Co. (003036) closed at 18.16, down 9.92% with a trading volume of 286,500 shares and a turnover of 542 million yuan [2] - Keda Manufacturing (66t0009) closed at 12.40, down 5.42% with a trading volume of 744,600 shares [2] - Ruitong Co. (603036) closed at 21.44, down 4.63% with a trading volume of 97,500 shares [2] Capital Flow - The specialized equipment sector experienced a net outflow of 406 million yuan from institutional investors, while retail investors saw a net inflow of 388 million yuan [2] - The top stocks by net inflow from retail investors included Lansi Heavy Industry (603169) with a net inflow of 2.19 billion yuan [3] - The top stocks by net outflow from institutional investors included Zhonghua Equipment (600579) with a net outflow of 32.43 million yuan [3]